Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

GPs are free to prescribe semaglutide to all eligible patients in line with NICE guidelines after long-term shortages have ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Bacterial vaginosis affects nearly a third of women worldwide and can cause infertility, premature births and newborn deaths.

Additionally, GLP-1 agonists such as dulaglutide, semaglutide and liraglutide have been shown to provide cardiovascular benefits. Doctors may also recommend these GLP-1 agonists to reduce the risk ...

Advt Eli Lilly's Trulicity (dulaglutide) was the most commonly used GLP-1 drug in the study. Some patients received Novo Nordisk's Ozempic (semaglutide) or the company's older Victoza (liraglutide).

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...